近来，欧洲白血病网络（ELN）修改了其急性髓系白血病（AML）基因风险分类。我们根据2022年和2017年ELN分类法，对接受紫杉醇/蒽环类药物治疗的1637名成年AML患者进行了分类。与2017年ELN分类相比，2022年有利组的患者比例从40％降至35％，不良组的患者比例从37％增加至41％。2022年的基因风险组似乎能够准确反映所有患者和<60岁患者的治疗结果，但在≥60岁的患者中，中等和不良组之间的复发率、无病生存期（DFS）和总生存期（OS）没有显着差异。在年轻的非裔美国患者中，DFS和OS在中等风险和不良风险患者之间没有差异，而在有利和中等组之间的DFS也没有差异。在西班牙裔患者中，DFS和OS在有利和中等组之间也没有差异。2022年和2017年ELN分类法的预后预测能力类似。在有利风险患者中，与CEBPAbZIP突变或核心结合因子AML患者相比，髓增生异常综合征相关的突变不会影响患者，但会将NPM1突变/ FLT3-ITD阴性患者的风险分配更改为中等。具有不良风险细胞遗传学异常的NPM1突变患者在预测方面更接近于中等而不是不良组。我们的分析既证实了一些新添加标记的预后意义，又挑战了一些标记的预后意义。 ©2023年作者（S）。

Recently, the European LeukemiaNet (ELN) revised its genetic-risk classification of acute myeloid leukemia (AML). We categorized 1637 adults with AML treated with cytarabine/anthracycline regimens according to the 2022 and 2017 ELN classifications. Compared with the 2017 ELN classification, 2022 favorable group decreased from 40% to 35% and adverse group increased from 37% to 41% of patients. The 2022 genetic-risk groups seemed to accurately reflect treatment outcomes in all patients and patients aged <60 years, but in patients aged ≥60 years, relapse rates, disease-free (DFS) and overall (OS) survival were not significantly different between intermediate and adverse groups. In younger African-American patients, DFS and OS did not differ between intermediate-risk and adverse-risk patients nor did DFS between favorable and intermediate groups. In Hispanic patients, DFS and OS did not differ between favorable and intermediate groups. Outcome prediction abilities of 2022 and 2017 ELN classifications were similar. Among favorable-risk patients, myelodysplasia-related mutations did not affect patients with CEBPAbZIP mutations or core-binding factor AML, but changed risk assignment of NPM1-mutated/FLT3-ITD-negative patients to intermediate. NPM1-mutated patients with adverse-risk cytogenetic abnormalities were closer prognostically to the intermediate than adverse group. Our analyses both confirm and challenge prognostic significance of some of the newly added markers.© 2023. The Author(s).